Syensqo (SYENS) investor relations material

Executive summary

• Achieved 5% year-over-year organic sales growth in Q2 2026, led by 18% growth in Composite Materials and a return to growth in Specialty Polymers.

• Gross profit reached €528 million with a 34% margin, up 100 basis points year-over-year.

• Underlying EBITDA was €311 million (20% margin), up 24% sequentially but down 6% year-over-year.

• Strategic review of the Performance & Care segment was launched, with advisors appointed to evaluate options and maximize shareholder value.

• Operating cash flow increased to €131 million, driven by positive working capital effects and the absence of separation costs.

Financial highlights

• Net sales for Q2 2026 were €1.55 billion, up 4% year-over-year and 11% sequentially.

• Gross profit margin improved to 34%, up 100 basis points year-over-year.

• Underlying EBITDA of €311 million, up 24% sequentially but down 6% year-over-year due to higher variable compensation and incremental costs.

• Operating cash flow was €131 million in Q2, up 60.4% sequentially and €111 million year-over-year.

• Capital expenditure for the quarter was €95 million, down 16% year-over-year; full-year guidance remains at €450 million.

Outlook and guidance

• Full-year 2026 underlying EBITDA outlook raised to at least €1.1 billion, reflecting improved volume outlook.

• Operating cash flow guidance unchanged at approximately €700 million; capital expenditure guidance also unchanged at €450 million.

• Full-year volume growth outlook raised to low to mid-single digits, led by Specialty Polymers and improved order book in Materials.

• Q3 EBITDA expected to be broadly in line with Q2, with continued caution due to geopolitical uncertainty.